EIA Terms and Conditions

Mallinckrodt 2020

Advancing ECP Immunomodulation Investigator Award in Graft versus host disease:
Refining THERAKOS ECP Immunomodulation™

Terms and Conditions

The following terms and conditions apply:

  • Submissions must demonstrate a significant focus on investigating the mechanisms behind THERAKOS ECP Immunomodulation™ in the field of Graft versus Host disease.
  • As part of the application process, applicants are required to provide a detailed outline of their plans for the grant funding according to the above-mentioned criteria. The provided template might serve as a guide for your application, but other formats are acceptable as well.
  • Applications without a detailed budget justification will not be accepted.
  • Project proposal must not only demonstrate a reasonable and detailed budget but also feasibility within a timeline of 18 months.
  • All submissions must be in English.
  • The winner must complete and sign the grant contract within an agreed timeline after selection. Failure to execute the contract in a timely manner may result in default of the award, in which case the runner-up would receive the award.
  • Projects are expected to be completed within 18 months following the distribution of funds.
  • Awardees are not nominated nor selected as an inducement or reward for purchasing, prescribing, using or recommending Mallinckrodt products.
  • Details of the award will also be declared in line with Transparency Reporting requirements.